Valuation: Biogen Inc.

Market Cap 32.27B 28.82B 26.89B 24.42B 45.96B 3,126B 46.41B 323B 126B 1,588B 121B 119B 5,108B P/E 2026 *
35.6x
P/E 2027 * 19.3x
Enterprise Value 37.21B 33.23B 31B 28.16B 52.99B 3,604B 53.51B 372B 146B 1,831B 140B 137B 5,890B EV / Sales 2026 *
3.56x
EV / Sales 2027 * 3.26x
Free-Float
85.8%
Yield 2026 *
-
Yield 2027 * -
1 week-2.47%
Current month-2.99%
1 month+6.45%
3 months+10.44%
6 months+25.85%
Current year+29.87%
1 week 192.56
Extreme 192.56
203.5
1 month 180.12
Extreme 180.12
203.5
3 years 98.5
Extreme 98.5
254.6
5 years 0
Extreme 0
318
10 years 0
Extreme 0
374.8
Manager TitleAgeSince
Chief Executive Officer 66 2022-11-13
Director of Finance/CFO 60 2025-02-28
Chief Tech/Sci/R&D Officer - 2024-10-27
Director TitleAgeSince
Director/Board Member 69 2010-03-22
Director/Board Member 77 2009-12-31
Director/Board Member 72 2019-06-18
Change 5-day change 1-year change 3-year change Capi.($)
-1.73%-1.28%+50.28%-22.34% 32.82B
-1.61%+1.72%+38.30%+106.93% 1,060B
-0.76%-0.84%+35.21%+62.70% 623B
+0.39%+4.81%+17.81%+83.77% 480B
-0.29%-0.99%+64.79%+37.06% 352B
-2.03%+1.06%+21.08%+42.16% 345B
-1.92%-0.29%+10.54%+33.20% 274B
-2.36%-1.16%-7.14%+8.68% 249B
-1.37%+0.04%+38.29%+52.33% 223B
+0.17%-0.27%+24.40%+96.82% 182B
Average -1.07%+0.47%+29.36%+50.13% 420.89B
Weighted average by Cap. -1.05%+0.74%+30.59%+68.04%

Financials

2026 *2027 *
Net sales 10.45B 9.33B 8.7B 7.9B 14.87B 1,012B 15.02B 104B 40.86B 514B 39.22B 38.37B 1,653B 10.66B 9.52B 8.88B 8.06B 15.17B 1,032B 15.32B 107B 41.69B 524B 40.01B 39.14B 1,687B
Net income 991M 885M 826M 750M 1.41B 96.01B 1.43B 9.91B 3.88B 48.79B 3.72B 3.64B 157B 1.88B 1.68B 1.57B 1.42B 2.68B 182B 2.7B 18.8B 7.35B 92.5B 7.06B 6.9B 297B
Net Debt 4.94B 4.41B 4.11B 3.74B 7.03B 478B 7.1B 49.38B 19.31B 243B 18.54B 18.13B 781B 2.42B 2.16B 2.02B 1.83B 3.45B 234B 3.48B 24.2B 9.47B 119B 9.09B 8.89B 383B
Projected Income Statement - Annual - Biogen Inc.
Logo Biogen Inc.
Biogen Inc. is one of the world's leaders in the design, manufacturing, and marketing of therapeutic products. Net sales break down by source of income as follows: - sales of medicines (72%): for treating multiple sclerosis, chronic psoriasis in adults, rheumatoid arthritis, cancers, etc.; - royalties (7.4%) ; - other (20.6%): primarily revenues from partnership agreements.
Employees
-
Date Price Change
26-10-08 €194.16 -1.73%
26-10-07 €197.58 -0.52%
26-10-06 €198.62 -0.02%
26-10-05 €198.66 +1.41%
26-10-02 €195.90 -1.60%
Trader
Investor
Global
Quality
ESG MSCI
AA
Ratings Surperformance© - Biogen Inc.
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
35
Last Close Price
218.43USD
Average target price
238.05USD
Spread / Average Target
+8.98%

Quarterly revenue - Rate of surprise

Rate of surprise - Net sales - Quarterly - Biogen Inc.